Market Closed - Nyse 04:10:00 2024-03-28 pm EDT 5-day change 1st Jan Change
0.45 USD +26.38% Intraday chart for BiomX Inc. +24.28% +60.71%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Biomx Inc. Announces Board Changes CI
BiomX Inc. announced that it has received $50.013969 million in funding from Deerfield Management Company, LLC, AMR Action Fund GP, LLC, Cystic Fibrosis Foundation, Nantahala Capital Management, LLC, OrbiMed Advisors LLC CI
BiomX Inc. completed the acquisition of Adaptive Phage Therapeutics, Inc. CI
Sector Update: Health Care Stocks Advance Wednesday Afternoon MT
Sector Update: Health Care MT
BiomX Shares Rally After Merger Deal With Adaptive Phage Therapeutics MT
Transcript : BiomX Inc., Adaptive Phage Therapeutics, Inc. - M&A Call
BiomX Inc. announced that it expects to receive $50.013969 million in funding from Deerfield Management Company, LLC, AMR Action Fund GP, LLC, Cystic Fibrosis Foundation, Nantahala Capital Management, LLC, OrbiMed Advisors LLC CI
BiomX Inc. agreed to acquire Adaptive Phage Therapeutics, Inc. for $11.5 million. CI
BiomX Says Data From Phase 1b/2a Trial of BX004 Showed 'Meaningful' Improvement in Pulmonary Function MT
Transcript : BiomX Inc. - Special Call
Biomx Announces Positive Topline Results from Part 2 of the Phase 1B/2A Trial Evaluating Bx004 for Treatment of Chronic Pulmonary Infections in Patients with Cystic Fibrosis CI
BiomX Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Biomx to Present Data from Ongoing Phase 1B/2A Study Evaluating Bx004 for the Treatment of Chronic Pseudomonas Aeruginosa Pulmonary Infections in Patients with Cystic Fibrosis CI
BiomX Inc. Announces the Appointment of Edward L. Williams to its Board of Directors CI
BiomX Inc. Announces Completion of Patient Dosing in Part 2 of Phase 1b/2a Study Evaluating BX004 for Treatment of Chronic Pulmonary Infections in Patients with Cystic Fibrosis CI
Transcript : BiomX Inc., Q2 2023 Earnings Call, Aug 09, 2023
BiomX Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Biomx Inc. to Present Part 1 Data from Phase 1B/2A Study Evaluating Bx004 for the Treatment of Chronic Pseudomonas Aeruginosa Pulmonary Infections in Patients with Cystic Fibrosis During Late-Breaking Science Session At The46th European Cystic Fibrosis Conference CI
BiomX Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
HC Wainwright Cuts Price Target on BiomX to $7 From $10, Maintains Buy Rating MT
Transcript : BiomX Inc., Q1 2023 Earnings Call, May 15, 2023
Biomx Inc. Appoints Jason M. Marks and Michael E. Dambach to the Board of Directors CI
BiomX Inc. announced that it has received $7.496224 million in funding from Cystic Fibrosis Foundation, OrbiMed Advisors LLC CI
BiomX Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Chart BiomX Inc.
More charts
BiomX Inc., formerly Chardan Healthcare Acquisition Corp., is a microbiome company. The Company is focused on developing both natural and engineered phage therapies. It develops therapies to target and destroy bacteria that affect the appearance of skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel disease (IBD), primary sclerosing cholangitis (PSC) and cancer. The Company discovers and validates bacterial targets and customizes phage compositions against the targets. Its pipeline includes BX001, BX002 and BX003. BX001 is a product candidate that improves the appearance of acne-prone skin. BX002 is a customized phage cocktail that eradicates bacterial targets associated with the onset of IBD. BX003 is a customized phage cocktail developed against specific strains of Klebsiella pneumoniae (Kp).
Calendar
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.45 USD
Average target price
3 USD
Spread / Average Target
+566.67%
Consensus